Press release
Global Rituximab Biosimilar Market Assessment- 2019 with the Analysis of Key Players Such as Amgen, AryoGen Pharmed, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Teva Pharmaceutical, Intas Biopharmaceuticals, JHL Biotech, mAbxience SA., Mylan,
Request for ToC/Proposal: https://bit.ly/2YP2B3F
Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the normal and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma as well as autoimmune disorder such as Rheumatoid arthritis. Rituximab is marketed under the trade name of MabThera in Europe and rest of World, except Japan by Roche. In the United States it marketed as Rituxan by Genentech in partnership with Biogen Idec. In Japan it is marketed by Chugai and Zenyaku Kogyo Co. Ltd. It is approved in the U.S. in 1997 and by European Medical Agency in June 1998. Rituximab is one of the top selling pharmaceutical product of Roche Holding AG. Therefor many biosimilar pharmaceutical companies are focusing on product development of rituximab biosimilar to compel the biosimilar product market share.
The rituximab biosimilar market is expected to grow at higher pace during forecast period,since the rituximab is one of the best seller drug product that accounts for around 2.1 million prescriptions worldwide since the market launch. In addition, rituximab has lost its patent in the United States and Europe in 2016 and 2013 respectively.
The Rituximab biosimilar market is fragmented with presence of many players that operates in local as well as international market.
Global Rituximab biosimilar Market reports cover prominent players like Amgen, AryoGen Pharmed, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Teva Pharmaceutical, Intas Biopharmaceuticals, JHL Biotech, mAbxience SA., Mylan, Pfizer, Sandoz, Zenotech Laboratories and many more.
Curious about this latest version of report?
Obtain Report Details @ https://bit.ly/2YP2B3F
Market Segments
• Global Rituximab biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Application
o Non-Hodgkin’s lymphoma,
o Chronic Lymhocytic Leukemia,
o Rheumatoid arthritis and others
• Global Rituximab Biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Distribution Channel
o Hospital Pharmacy
o Online Pharmacy
o Retail Pharmacy
o Other Direct Distribution Channels
Why should buy this report:
To receive a comprehensive analysis of the prospects for global Rituximab biosimilar market
To receive industry overview and future trends Rituximab biosimilar market
To analyze the Rituximab biosimilar market drivers and challenges
To get information on Rituximab biosimilar market size and forecast
To get details on Rituximab biosimilar clinical trial/pipeline analysis
Originator drug historic revenue
Originator drug key news/industry activities
Major Mergers & Acquisition in Rituximab biosimilar industry
Request for ToC/Proposal: https://bit.ly/2YP2B3F
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2EgGlWR
Follow Us On Facebook @ bit.ly/2H9jnDZ
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Rituximab Biosimilar Market Assessment- 2019 with the Analysis of Key Players Such as Amgen, AryoGen Pharmed, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Teva Pharmaceutical, Intas Biopharmaceuticals, JHL Biotech, mAbxience SA., Mylan, here
News-ID: 1785595 • Views: …
More Releases from InsightAce Analytic Pvt. Ltd.
Organic Feminine Care Market to Benefit from Increasing Government Initiatives a …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Organic Feminine Care Market Size, Share & Trends Analysis Report By Product Type (Sanitary Pads, Tampons, Menstrual Cups, Liners and Shields, Others), by Nature (Disposable, Reusable), by Age Group (Upto 18 Years, 19-30 Years, 31-40 Years, 41 Years and Above), by Distribution Channel (Supermarkets and hypermarkets, Pharmacy, Online Stores, Others)- Market Outlook And Industry Analysis…
Intravenous Immunoglobulin Market Key Players Analysis - Biotest AG, Octapharma …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel (hospital pharmacies, speciality pharmacies), Region, Market Outlook And Industry Analysis 2031"
The global Intravenous Immunoglobulin market is estimated to reach over USD 21.22 billion by 2031, exhibiting a CAGR of 6.60% during the forecast period.
Get Free Access…
Exascale Computing Market Key Players Analysis- Hewlett Packard Enterprise Compa …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Exascale Computing Market - (By Component (Hardware, Software, Services), By Deployment (On-premises, Cloud-based), By Customer Type (Government & Defense, Healthcare & Biosciences, Financial Services, Research & Academia, Manufacturing & Energy, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Exascale Computing Market is valued at…
Plasma Fractionation Market Robust Expansion is expected to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Plasma Fractionation Market- (By Product (Immune-Globulins(Intravenous Immune-Globulins, Subcutaneous Immune-Globulins, Other Immune-Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Others), Albumin, Protease Inhibitors, Other Plasma Products), By Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato-Oncology, Rheumatology, Others), By End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes)),…
More Releases for Rituximab
Rituximab Production Cost Analysis Report by Procurement Resource
Procurement Resource, a globally trusted name in procurement intelligence and production cost analysis, proudly presents its latest Rituximab Production Cost Report. This report is an indispensable guide for pharmaceutical companies, contract manufacturing organizations (CMOs), biosimilar developers, and investors aiming to understand the technical, financial, and operational intricacies of producing this critical monoclonal antibody.
Rituximab Production Cost Analysis Report: https://www.procurementresource.com/production-cost-report-store/rituximab
Rituximab: A Lifesaving Biologic Therapy
Rituximab is a chimeric monoclonal antibody (mAb) that targets…
Prominent Rituximab Biosimilars Market Trend for 2025: Collaborative Innovations …
Which drivers are expected to have the greatest impact on the over the rituximab biosimilars market's growth?
The rituximab biosimilars market is anticipated to grow due to the projected increase in non-Hodgkin's lymphoma (NHL) cases. NHL is a cancer that originates in the white blood cells and lymphocytes, which are integral parts of the body's immune system. For example, the American Cancer Society, a cancer advocacy group based in the US,…
Rituxan Rituximab Drug Market: A Comprehensive Overview
the market size for Rituxan (rituximab) was estimated at approximately USD 7.5 billion in 2023 and is projected to reach around USD 12.9 billion by 2032, indicating a compound annual growth rate (CAGR) of approximately 6.5% from 2024 to 2032.
Rituxan Rituximab Drug Market Overview
The Rituxan (rituximab) drug market is a significant segment within the oncology and autoimmune disease treatment landscape. Rituxan, a monoclonal antibody, is primarily used to…
Global Rituximab Biosimilars Market Imapct of AI and Automation
Rituximab Biosimilars Market Impact of AI and Automation
The global Rituximab biosimilars market was valued at approximately $6.2 billion in 2022, with an anticipated compound annual growth rate (CAGR) of 10.5% from 2023 to 2030. This growth reflects the increasing adoption of biosimilars due to their cost-effectiveness compared to originator biologics, combined with rising patient populations and expanding indications for Rituximab. The market's robust expansion is underpinned by an increasing number…
Rituximab Market Trends, Insights and Future Outlook 2022-2029
This Rituximab Market report has been prepared by considering several fragments of the present and upcoming market scenario. The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. It consists of most-detailed market segmentation, thorough analysis of major market players, trends in consumer and supply chain…
Rituximab Biosimilars Market Size, Share, Report and Forecast 2024-2032
Rituximab Biosimilars Market Outlook
The rituximab biosimilars market size was valued at USD 2.37 billion in 2023 and is projected to grow at a CAGR of 15.7% during the forecast period of 2024-2032 to reach a value of USD 8.81 billion by 2032. The market growth can be attributed to the increasing prevalence of autoimmune diseases, and cancer, and the rising demand for cost-effective alternatives to branded biologics.
Rituximab Biosimilars: Introduction
Rituximab biosimilars…
